OverviewSuggest Edit

Ultivue is an early stage life sciences tools company that seeks to provide the ultimate view into biology. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that vastly improve our understanding of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use. The company's patented technologies enable single molecule detection and visualization of a multitude of biomolecules, including proteins and nucleic acids, the key drivers of cellular functions and indicators of disease states.
HQCambridge, MA, US
Employee Ratings2.8

Latest Updates

Employees (est.) (Jan 2022)109(+3%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Ultivue

Jacques Corriveau

Jacques Corriveau

President and CEO
Martin Madaus

Martin Madaus

Richard Malabre

Richard Malabre

Chief Financial Officer
Barry Lynch

Barry Lynch

Vice President, Global Sales and Field Support
Mike Sismour

Mike Sismour

Vice President of Research
Keith Wharton

Keith Wharton

Vice President, Medical Director
Show more

Ultivue Office Locations

Ultivue has offices in Cambridge and Segrate
Cambridge, MA, US (HQ)
763d Concord Ave
Segrate, IT
Via Calabria, 15
Show all (2)

Ultivue Financials and Metrics

Summary Metrics

Founding Date


Ultivue total Funding

$57.3 m

Ultivue latest funding size

$22 m

Time since last funding

3 years ago

Ultivue investors

Ultivue's latest funding round in June 2019 was reported to be $22 m. In total, Ultivue has raised $57.3 m
Show all financial metrics

Ultivue Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Ultivue Online and Social Media Presence

Embed Graph

Ultivue News and Updates

Fluidigm Announces Co-Marketing Agreement with Ultivue for Biomarker Imaging Solutions for Precision Medicine

Objective of Agreement is Comprehensive Portfolio for Biomarker Discovery and Drug Development Objective of Agreement is Comprehensive Portfolio for Biomarker Discovery and Drug Development

Northpond Ventures leads Series C round for Ultivue

Cambridge, Massachusetts-based Ultivue, a provider of tissue biomarker identification and quantification assays for translational and pathology research labs, has secured $22 million in Series C funding. Northpond Ventures led the round with participation from other investors that included ARCH Vent…

Ultivue Frequently Asked Questions

  • When was Ultivue founded?

    Ultivue was founded in 2015.

  • Who are Ultivue key executives?

    Ultivue's key executives are Jacques Corriveau, Martin Madaus and Richard Malabre.

  • How many employees does Ultivue have?

    Ultivue has 109 employees.

  • Who are Ultivue competitors?

    Competitors of Ultivue include SQZ Biotech, Santa Cruz Biotechnology and Foghorn Therapeutics.

  • Where is Ultivue headquarters?

    Ultivue headquarters is located at 763d Concord Ave, Cambridge.

  • Where are Ultivue offices?

    Ultivue has offices in Cambridge and Segrate.

  • How many offices does Ultivue have?

    Ultivue has 2 offices.